• Mashup Score: 1
    JNCCN 360 - AML - SOHO 2022: Prognostic Value of MRD in Patients With Aggressive AML - 1 year(s) ago

    By: Vanessa A. Carter, BS Posted: Tuesday, October 25, 2022 Michael Heuser, MD, of Hannover Medical School, Germany, aimed to determine whether a measurable residual disease (MRD) assessment is more prognostic than the initial presentation of characteristics in patients with acute myeloid leukemia (AML). Presented…

    Source: jnccn360.org
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of CyclingDoctor
      CyclingDoctor

      RT @JNCCN: #SOHO2022: Prognostic Value of MRD in Patients With Aggressive #AML: https://t.co/vTvPUJXwc6 #leusm #hemeonc #AMLsm #JNCCN360 ht…

  • Mashup Score: 2
    JNCCN 360 - CLL - SOHO 2022: Are B-Cell Receptor Stereotypes Indicative of Patient Outcomes in CLL? - 2 year(s) ago

    By: Vanessa A. Carter, BS Posted: Friday, October 14, 2022 During the 2022 Society of Hematologic Oncology (SOHO) Annual Meeting (Abstract EXABS-176-CLL), Kostas Stamatopoulos, MD, PhD, of the Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece, reflected on the clinical…

    Source: jnccn360.org
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of CyclingDoctor
      CyclingDoctor

      RT @JNCCN: #SOHO2022: Are #BCell Receptor Stereotypes Indicative of Patient Outcomes in #CLL? https://t.co/0MArWkCAIR #leusm #CLLsm #JNCCN3…

    • Profile photo of JNCCN
      JNCCN

      #SOHO2022: Are #BCell Receptor Stereotypes Indicative of Patient Outcomes in #CLL? https://t.co/0MArWkCAIR #leusm #CLLsm #JNCCN360 https://t.co/R82cq9jdZg

  • Mashup Score: 3
    JNCCN 360 - AML - SOHO 2022: New Insights on Venetoclax Resistance in AML - 2 year(s) ago

    By: Vanessa A. Carter, BS Posted: Thursday, October 13, 2022 During the 2022 Society of Hematologic Oncology (SOHO) Annual Meeting (Abstract EXABS-147-AML), Kapil Saxena, MD, of The University of Texas MD Anderson Cancer Center, Houston, and colleagues shared their reasoning as to why patients with acute myeloid…

    Source: jnccn360.org
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of CyclingDoctor
      CyclingDoctor

      RT @JNCCN: #SOHO2022: New Insights on Venetoclax Resistance in #AML: https://t.co/nDczsXiyRi #JNCCN360 #HemOnc #leusm https://t.co/8nSQfovu…

    • Profile photo of JNCCN
      JNCCN

      #SOHO2022: New Insights on Venetoclax Resistance in #AML: https://t.co/nDczsXiyRi #JNCCN360 #HemOnc #leusm https://t.co/8nSQfovu5L

  • Mashup Score: 1
    Gilteritinib Induces Encouraging Responses in Newly Diagnosed FLT3-Mutated AML - 2 year(s) ago

    Gilteritinib, in combination with induction and consolidation chemotherapy, generated responses in patients with newly diagnosed acute myeloid leukemia, including those with FLT3 mutations, according to data from a phase 1 trial.

    Source: OncLive
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of OncLive
      OncLive

      Gilteritinib, in combination with induction and consolidation chemotherapy, generated responses in patients with newly diagnosed acute myeloid leukemia, including those with FLT3 mutations, according to data from a phase 1 trial. #SOHO2022 #leusm https://t.co/WDNIkgKpjC https://t.co/jr4xlN9aJy

  • Mashup Score: 0
    The Cancer News Daily - 2 year(s) ago

    The latest in cancer medicine and translational research by Wafik El-Deiry MDPhD

    Source: paper.li
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of weldeiry
      weldeiry

      The latest The Cancer News Daily! https://t.co/yE8ezw2Rji Thanks to @Lymphomation @Aiims1742 @rschilsky #pancchat #soho2022

  • Mashup Score: 3
    Gilteritinib Induces Encouraging Responses in Newly Diagnosed FLT3-Mutated AML - 2 year(s) ago

    Gilteritinib, in combination with induction and consolidation chemotherapy, generated responses in patients with newly diagnosed acute myeloid leukemia, including those with FLT3 mutations, according to data from a phase 1 trial.

    Source: OncLive
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of OncLive
      OncLive

      Gilteritinib, in combination with induction and consolidation chemotherapy, generated responses in patients with newly diagnosed acute myeloid leukemia, including those with FLT3 mutations, according to data from a phase 1 trial. #SOHO2022 #leusm https://t.co/KoNnRzER0T

Load More